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1. Introduction 
Age-related macular degeneration (AMD) is a leading cause of irreversible visual 
impairment and blindness in the aging population 1. Yet, individuals with AMD have 
limited treatment options. Given the high prevalence and considerable public health 
burden, it is essential to understand the etiology and pathogenesis of AMD. 
AMD is a multifactorial disease, with complex genetics and confounding environmental  
risk factors. The etiology of AMD still remains unknown, but oxidative stress to the retina 
and the retinal pigment epithelium (RPE) is one of the leading hypotheses in AMD 
pathogenesis. 
2. Oxidative stress and AMD 
Oxidative stress and the cellular damages caused by reactive oxygen species (ROS) has been 
implicated in aging and age-related eye diseases 2. Most intracellular ROS are derived from 
the mitochondria in the electron transport chain. During fuel metabolism, oxygen 
consumption and ATP synthesis in the mitochondria, electrons are shuffled in sequential 
reduction and oxidation reactions in the electron transport chain. Yet, these reactions are not 
100% efficient; electrons may “leak” out and result in the formation of ROS. ROS are highly 
reactive and unstable oxygen-containing atoms, ions, or molecules such as hydroxyl radical 
(OH), superoxide anion (O2-) and hydrogen peroxide (H2O2). Due to the presence of the 
“unpaired” electron in the outer shell, ROS are very unstable. In trying to achieve stability, 
ROS will then participate in further reduction and oxidation reactions, oxidizing target 
molecules and resulting in generation of other free radicals by chain reaction.  
Oxidative damages by ROS affect DNA and lipids inside the cell. Earlier senescence, which 
may be related to shortening of telomeric DNA, occurs after oxidative damage 3-6. Oxidative 
damage also results in point mutations and deletions in mitochondrial DNA 7. In fact, 
mitochondrial DNA is more susceptible to ROS-induced damage than nuclear DNA 8. As for 
lipids, ROS causes oxidation of lipid in a process called lipid peroxidation. The 
polyunsaturated fatty acids, a common and significant component of cell membrane, are 
particularly vulnerable to oxidation by ROS as a result of their many conjugated double 
bonds. Oxidation of polyunsaturated fatty acids results in the formation of reactive 
aldehyde intermediates which are toxic to the cell 9. 
www.intechopen.com
 
Age Related Macular Degeneration – The Recent Advances in Basic Research and Clinical Care 
 
186 
The retina is a structure that is particularly susceptible to oxidative damage by ROS. Firstly, 
the retina has the highest oxygen consumption in the body 10. In addition, constant exposure to 
incoming light in the retina can lead to photo-oxidation. The high oxygen consumption and 
high light exposure in the retina may in turn generate ROS. Moreover, the retina has a high 
lipid content, with abundant polyunsaturated fatty acids in the photoreceptor outer segments 
which are most prone to lipid peroxidation. In the neighborhood of photoreceptors are the 
RPE cells. Besides providing metabolic support to the photoreceptors, they also phagocytose 
the constantly shed parts of the photoreceptor outer segments. All these factors contribute to 
the susceptibility of the retina and RPE to oxidative stress.  
With age, the susceptibility to oxidative damage in the retina increases. Aged rat retina 
showed decreased GSH-Px and catalase activities, which are related to increased lipid 
peroxidation with age 11. In particular, RPE cells accumulate lipofuscin granules during life. 
Lipofuscin granules are lysosomal residual bodies containing undigested end products from 
phagocytosis of photoreceptor outer segments 12. It was estimated that lipofuscin can 
occupy up to 19% of RPE cytoplasmic volume by the age of 80 when compared with only  
1 % during the first decade of life 13. Lipofuscin has been shown to contain toxic substances, 
such as retinoids (products of the visual cycle) and oxidized proteins 14. Lipofuscin was also 
able to reduce RPE lysosomal and antioxidant activity 15. In vitro studies using porcine RPE 
cells showed that visible light irradiation can degrade RPE melanosomes, reduce melanin 
amount and increase ROS production, changes that also occur in human RPE melanosomes 
with aging 16.  
3. Nutritional supplements and AMD 
Oxidative stress has a recognized role in aging and AMD; treatments for AMD are therefore 
aimed at reducing oxidative stress-induced damage within the retina and RPE cells. This can 
be approached in two ways, either by decreasing the source of oxidative stress or by 
increasing the defense against oxidative stress. Among them, a tempting measure in 
lowering oxidative damage would be by dietary antioxidant supplementation. Data from 
observational studies have supported a link between nutritional factors with antioxidant 
properties and risks of AMD 17,18. Carotenoids, vitamin C and vitamin E with their 
antioxidant properties have been identified as having a potentially protective role. Other 
nutrients such as zinc and omega-3 fatty acids have been shown to be associated with 
reduced risk of AMD. Recently, B vitamins (folic acid, B6 and B12) have also been proposed 
to provide protection by a non-oxidative mechanism. Another nutritional supplement that 
has gained interest recently is the extracts from a group of fruit, berries.  
Common nutrition supplements include: 
1. AREDS and AREDS-type formulation 
2. Carotenoids (β-carotene, lutein and zeaxanthin) 
3. Vitamin C (L-ascorbic acid) 
4. Vitamin E (α-tocopherol)) 
5. Zinc 
6. Omega-3 Long chain polyunsaturated fatty acids 
7. B vitamins 
8. Berry extracts 
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A summary of studies investigating the effect of nutritional supplements on the prevention 
and progression of AMD is shown in Tables 1 and 2. 
 
 Study 
Nutrients  
investigated  
participants 
(number; age) 
Follow-up 
Randomized trials 
Teikari 1998 43 
Alpha-tocopherol and 
beta-carotene study 
(ATBC) 
beta-carotene; 
vitamin E  
Finland (941; ≥65 
years old) 
6-year 
prevalence 
Taylor 2002 74 
Vitamin E, cataract, 
and age related 
maculopathy trial 
(VECAT) 
vitamin E  
Australia (1,193; 55-
80 years old) 
4-year 
incidence 
Christen 2009 132 
Women's  
Antioxidant and  
Folic Acid 
Cardiovascular  
Study (WAFACS) 
folic acid/B6/B12 
Female health care 
professionals  
in USA  
(5,442; ≥40 years ) 
Av 7.3 years 
Christen 2010 75 
Women’s Health 
Study (WHS) 
vitamin E 
Female health 
professionals  
in USA  
(39,876; ≥45 years) 
Av 10 years 
follow up 
Weigert 2011 61 
Lutein Intervention 
Study Austria  
(LISA) 
lutein 126 AMD patients 
6-month 
follow up 
Population-based studies
VandenLangenberg 
et al 23 
Beaver Dam study 
alpha-carotene; beta-
carotene; beta 
cryptoxanthin; lutein 
+ zeaxanthin; 
lycopene; vitamin E; 
zinc; fruit and 
vegetables; 
supplements 
USA (1,709; 43-84 
years old) 
5-year 
incidence 
Smith 2000 107 
The Blue Mountains 
Eye Study (BMES) 
dietary fat, fish 
Australia (3654; ≥49 
years old) 
 
Cho 2001 88 
Nurses’ Health Study 
(NHS) and Health 
Professional Follow-
up Study (HPFS) 
zinc 
Health 
professionals in 
USA (104,208: 
66,572 women, 
37,636 men; ≥50 
years old) 
8-10 year 
incidence 
Cho 2001 108 
Nurses’ Health Study 
(NHS) and Health 
Professional Follow-
up Study (HPFS) 
Dietary fat 
Health 
professionals in 
USA (72,489: 42,743 
women, 29,746 men; 
≥50 years old) 
 
Heuberger 2001 145 
Third National 
Health and Nutrition 
Examination Study 
(NHANES III) 
Dietary fat 
USA (11,448; 40-79 
years old) 
 
www.intechopen.com
 
Age Related Macular Degeneration – The Recent Advances in Basic Research and Clinical Care 
 
188 
 Study 
Nutrients  
investigated  
participants 
(number; age) 
Follow-up 
Flood 2002 44 
The Blue Mountains 
Eye Study (BMES) 
alpha-carotene; beta-
carotene; beta 
cryptoxanthin; lutein 
+ zeaxanthin; 
lycopene; vitamin A; 
vitamin C; zinc; 
supplements
Australia (1,989; ≥49 
years old) 
5-year 
incidence 
Cho, 2004 52 
Nurses' Health Study 
and men in the 
Health Professionals 
Follow-up Study 
alpha-carotene; beta-
carotene; beta 
cryptoxanthin; lutein 
+ zeaxanthin; 
lycopene; vitamin A; 
vitamin C; vitamin E; 
fruits and vegetables; 
supplements
Health 
professionals in 
USA (118,428; ≥50 
years old) 
12-18 year 
incidence 
van Leeuwen 2005 
42 
Rotterdam Eye Study
alpha-carotene; beta-
carotene; beta 
cryptoxanthin; lutein + 
zeaxanthin; lycopene; 
vitamin A; vitamin C; 
vitamin E; zinc 
Netherlands (4,170; 
≥55 years old) 
Mean 8-year 
follow-up 
Chua 2006 110 
The Blue Mountains 
Eye Study (BMES)
omega-3 fatty acid; 
fish
Australia (3654; ≥49 
years old)
5-year 
incidence 
Moeller 2006 53 
Carotenoids in  
Age-related  
Eye Disease  
Study (CAREDS) 
lutein + zeaxanthin; 
fruit and vegetable 
Women's Health 
Initiative  
(1,787; 50 to  
79 years old), 
women only
6 year 
prevalence 
Delcourt 2007 112 
Pathologies Oculaires 
Liees a IAge 
(POLANUT)
total fish; white fish; 
fatty fish 
France (832; ≥70 
years old) 
 
Augood 2008 114 EUREYE DHA; EPA; oily fish Europe (4,753)  
Cho 2008 54 
Nurses’ health Study 
and Health 
Professionals Follow-
up Study
lutein + zeaxanthin 
(113,058: 71,494 
women and 41,564 
men; ≥50 years old)
Up to 16 years 
in men, Up to 
18 years in 
women 
Wang 2008 117 
The Blue Mountains 
Eye Study (BMES) 
fish 
Australia (1,881; ≥49 
years old; CFH 
genotype)
10 year 
Tan 2008 45 
The Blue Mountains 
Eye Study (BMES) 
alpha-carotene; beta-
carotene; beta 
cryptoxanthin; lutein 
+ zeaxanthin; 
lycopene; vitamins A; 
vitamin C ; vitamin 
E; iron; zinc 
Australia (2,454; ≥49 
years old) 
Mean 5.1 years 
and 10.5 years 
Tan 2009 116 
The Blue Mountains 
Eye Study (BMES)
omega-3 fatty acid; 
fish
Australia (3654; ≥49 
years old)
10-year 
incidence 
Ho 2011 91 The Rotterdam Study
beta-carotene; 
lutein/zeaxanthin; 
DHA; EPA; zinc; 
Netherlands (2,167; 
≥55 years old; CFH 
and 
LOC387715/ARMS2 
genotype)
Mean 8.6 years 
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 Study 
Nutrients  
investigated  
participants 
(number; age) 
Follow-up 
Retrospective study 
Mares-Perlman 
1995 
Beaver Dam Study 
and Nutritional 
Factors in Eye 
Disease Study 
total fat;  
saturated fat;  
oleate; linoleate; 
cholesterol;  
seafood 
USA (2,152; 45-84 
years old) 
 
Klein 2008 90 AREDS AREDS, zinc 
USA (876; CFH and 
LOC387715/ARMS2 
genotype) 
 
Case controlled study
Seddon 2006 111 
US Twin Study of 
Age-Related Macular 
Degeneration 
omega-3 fatty acids; 
fish 
USA (681 twins; 
male only) 
 
SanGiovanni 2007 
113 
AREDS 
DHA;  
omega-3 fatty acids; 
fish 
USA (4,519; 60-80 
years old) 
 
Cross-sectional study
Chiu 2009 146 AREDS 
DHA; EPA; 
lutein/zeaxanthin; 
vitamin C; vitamin E; 
zinc 
USA (4,003)  
Table 1. Studies investigating nutritional supplements in the prevention of AMD 
 
 Study Nutrients investigated 
participants 
(number; age) 
Treatment 
duration 
Newsome 1988 24  zinc 
USA (151: 56 men, 95 
women; 42-89 years 
old) 
12-24 months 
Stur 1996 87  Zinc 
Austria (112: 48 men, 
64 women; ≥50 years 
old) 
24 months 
AREDS 19  
beta-carotene;vitamin 
C; vitamin E; copper; 
zinc  
USA (3640, 56% 
women; average 69 
years old) 
6 years 
Seddon 2001 109  Dietary fat, fish 
USA (349; 55-80 
years old) 
 
Richer 2004 55 
Veterans LAST 
study (Lutein 
Antioxidant 
Supplementation 
Trial)LAST 
lutein 
/antioxidants/vitamins 
and minerals broad 
spectrum 
supplementation 
formula 
USA (90: 86 men, 4 
women) 
12 months 
SanGiovanni 
2008 115 
AREDS omega-3 fatty acid; fish USA (2,132)  
Weigert 2011 61 
Lutein Intervention 
Study Austria 
(LISA) 
lutein 
Austria (126 AMD 
patients) 
6 months  
Table 2. Studies investigating nutritional supplements in the progression of AMD 
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3.1 AREDS and AREDS-type formulation 
The Age-Related Eye Disease Study (AREDS) was a clinical trial sponsored by the National 
Eye Institute 19. This was to date the largest prospective randomized controlled trial to 
investigate the effect of an active supplement formula on the risk of development of AMD. 
The dosages of the supplements were at a high-than-normal level, because it was considered 
a form of active treatment, instead of a simple supplement pill. There were a total of 3,640 
subjects, being monitored for an average of 6.3 years. Each subject was given either the 
AREDS formula, or placebo, to be taken on a twice-daily basis. Main components of the 
AREDS formula are vitamin A, vitamin C, vitamin E, and zinc. These were chosen because 
of their anti-oxidative abilities 20-25. When compared with the Dietary Reference Intake (DRI) 
issued by the Institute of Medicine, US National Academy, the dosage of ingredients in the 
AREDS formula was at a much higher level 26. For instance, the dosage of vitamin C in the 
AREDS formula was 500 mg/day, while that of the DRI was only 90mg per day. As far as 
vitamin C was concerned, one has to take at least 7 to 8 oranges per day, just to match up 
with what is provided by the AREDS pill 27. A comparison of the dosage in AREDS 
formulation with common fruits is given in Table 3. 
 
Nutrients Unit AREDS DRI* Apple# Orange# Banana# Blueberry# 
Vitamin A@ 
International 
Unit (IU) 
5000 3000 54 225 64 22 
Vitamin C 
milligram  
(mg) 
500 90 4.6 53.2 8.7 0.7 
Vitamin E mg 400 15 0.18 0.1 0.1 0.23 
Zinc mg 80 11 0.04 0.07 0.15 0.1 
Copper mg 2 0.9 0.027 0.045 0.078 0.12 
Lutein + 
Zeaxanthin 
microgram 
(µg) None No data ** 29 129 22 33 
@ Vitamin A as beta-carotene 
* Dietary Reference Intakes from the Institute of Medicine 
** 2.0-2.3 mg/day for men and 1.7-2.0 mg/day for women in United States  
(Food and Nutrition Board, 2001) 
# Nutrient contents of common fruits are expressed per 100 grams 
Table 3. Dosages of the Age-Related Eye Disease Study (AREDS) type formulas in 
comparison to common fruit items 
After categorizing the subjects according to their macular status (Table 4), they were then 
monitored serially with fundus photographs. Results of the AREDS were first released in 
2001. It showed a 25% risk reduction in progression to advanced AMD, for category 3 and 4 
subjects only. For other subjects, i.e. those under category 1 and 2, results were not 
statistically significant. In the US, 80% of those over 70 years of age fall under either 
category 1 or 2 28. Hence, the protection offered by the AREDS formula may not be 
applicable to all. Therefore, it was only recommended to high-risk individuals (those under 
category 3 or 4).  
Risk associated with regular intake of the AREDS formula was of particular concern, mainly 
because it was meant for long-term use. In particular, the risk of regular intake of such a 
high level of vitamins and minerals was unknown. Potentially, vitamin A (in the form of 
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beta-carotene) may be associated with an increased risk of lung cancer in smokers; vitamin 
C may cause renal stones; vitamin E may be associated with increased risk of hemorrhagic 
stroke; zinc can cause anemia, stomach upset, and may reduce serum high-density 
lipoprotein level.  
 
 Brief description Clinical features Visual acuity 
Category 1 No AMD in both eyes 
<5 small drusen in one or 
both eyes 
20/32 or better in both 
eyes 
Category 2 
Mild to borderline AMD 
in one or both eyes 
Multiple small or 
intermediate drusen in 
one or both eyes 
Pigment abnormalities in 
one or both eyes 
20/32 or better in both 
eyes 
Category 3 
Absence of advanced 
AMD in both eyes 
Intermediate or large 
drusen  
Geographic atrophy 
Features not involving 
central macula 
20/32 or better in better 
eye 
Category 4 
Advanced AMD in one 
eye 
Advanced AMD or 
geographic atrophy in 
worse eye 
No such features in better 
eye 
20/32 or better in better 
eye 
Key: small drusen, <63 um in diameter (disc diameter around 1500 um); intermediate drusen,  
63-124 um in diameter; large drusen, >125 um in diameter; pigment abnormalities refer to either 
hyperpigmentation or depigmentation 27 
Table 4. Categorization of AMD according to AREDS guidelines 
However, observations from the AREDS cohort failed to show any statistically significant 
serious side effects as mentioned above. Documented minor side effects included 1) 
increased genitourinary symptoms; 2) increased self-reported anemia; and 3) yellow 
discoloration of skin due to high level of vitamin A. Self-reported anemia was not correlated 
with any genuine reduction in blood hematocrit level. Smokers in the AREDS were 
discouraged from smoking, therefore whether the risk of lung cancer was increased was not 
being addressed. However, this has already been confirmed in two other trials 29,30. Hence, 
all smokers should be discouraged from smoking before the commencement of the AREDS 
formula. If he or she is not willing to quit smoking, the risk of having lung cancer may 
outweigh the potential benefit in AMD protection. 
In general, the AREDS formula was deemed safe and effective, in selected high-risk 
individuals 31. Inadequacy of the AREDS formula was that it did not include other potential 
ingredients such as lutein, zeaxanthin, and omega-3 fatty acid, which are also of particular 
interest due to their antioxidant abilities. In view of this, the National Eye Institute has 
launched the Age-Related Eye Disease Study 2 (AREDS2) in 2006, in hope to fill up the 
knowledge in this gap 32,33. In the AREDS2 formula, lutein, zeaxanthin, and omega-3 fatty 
acid have been added to the existing AREDS formula, and vitamin A was removed, mainly 
due to the potential risk associated with lung cancer. Results of the AREDS2 are expected to 
be available in 2012. Until then, the AREDS formula remains the only evidenced-based 
formula to reducing the risk of development of advanced AMD. 
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3.2 Carotenoids (β-carotene, lutein and zeaxanthin) 
Carotenoids are organic pigments naturally occurring in plants as well as in some algae, 
fungus and bacteria. Animals generally cannot synthesize carotenoids; they have to obtain 
carotenoids in their diet. There are two classes of carotenoids, xanthophylls (which contain 
oxygen) and carotenes (which are purely hydrocarbons, and contain no oxygen) accounting 
for over 600 known carotenoids. A well known carotene is beta-carotene, the pigment that 
makes carrots orange. Interestingly, there are only two carotenoids that are present in the 
human retina 34,35, namely lutein [(3R,3'R,6'R)-beta,epsilon-Carotene-3,3'-diol] and its 
stereoisomer, zeaxanthin [(3R,3'R)-beta,beta-Carotene-3,3'-diol]. These carotenoids are 
enriched in the macula in high concentrations, thus giving the macula its yellowish color.  
In human, four carotenoids including beta-carotene, alpha-carotene, gamma-carotene, and 
beta-cryptoxanthin can be converted into retinal, which is an important molecule in the 
photo-transduction pathway and therefore vision. Carotenoids can also absorb light and act 
as antioxidants by scavenging ROS such as .O2 and peroxyl radicals 36. In particular, two 
xanthophylls, lutein and zeaxanthin, have been shown to absorb the damaging blue light 36 
as well as protect the retina 37 and retinal ganglion cells 38 from oxidative damage in vitro. In 
animal studies, lutein protected the inner retina against acute retinal ischemia/reperfusion 
injury due to its antioxidant properties 39.  
Due to their antioxidant properties and blue light-filtering effects, the association of 
carotenoids with risk of AMD was explored. There have been conflicting results. Decreased 
risk of neovascular AMD has been found to be associated with higher levels of carotenoids 
in the serum samples 40. In monkeys, feeding a xanphophyll-free diet has been shown to 
promote drusen formation 41. In an early study based on National Health and Nutrition 
Examination Survey I data, an inverse association between the consumption of fruits and 
vegetables rich in pro-vitamin A carotenoids and the prevalence of AMD was demonstrated 
22. In the Beaver Dam Eye Study, VandenLangenberg et al also found a significant but 
modest inverse association between intake of pro-vitamin A carotenoids and the incidence 
of large drusen 23. Later studies using the AREDS formulation suggested a beneficial effect 
of beta-carotene 19. The Rotterdam population-based study also reported a high dietary 
intake of beta-carotene together with vitamins C and E and zinc reduced the risk of AMD in 
elderly individuals 42. A 35% reduced risk of AMD was observed when an above-median 
intake of these 4 nutrients was given.  
On the other hand, opposing results were obtained from other clinical trials and population-
based studies. The Alpha-Tocopherol and Beta-Carotene (ATBC) Study in Finland assessed 
the involvement of beta-carotene in occurrence of AMD among smoking males 43. Over 
29,000 smoking males aged 50 to 69 years were given alpha-tocopherol (50 mg/day), beta-
carotene (20 mg/day), both of these, or placebo randomly. After 5 to 8 years of 
supplementation, Teikari et al found no beneficial effect of long-term beta-carotene 
supplementation on the incidence of AMD. The Blue Mountains Eye Study also reported no 
associations between beta-carotene intake and 5-year incidence of AMD 44. This is a 
population-based study including 1,989 individuals who finished a food frequency 
questionnaire. This questionnaire assessed the baseline intake of nutrients including alpha-
carotene, beta-carotene, beta-cryptoxanthin, lutein and zeaxanthin, lycopene, retinol, 
vitamin A, vitamin C, and zinc. For beta-carotene, Teikari et al suggested no evidence of 
protection by beta-carotene on the 5-year incidence of AMD. Further studies in the same 
www.intechopen.com
 
Nutritional Supplement Use and Age-Related Macular Degeneration 
 
193 
population after 10-year of follow-up showed some interesting results. Instead of showing 
no effect of beta-carotene in AMD, Tan et al actually reported an increased risk of 
neovascular AMD with increasing beta-carotene intake 45. The authors found that increasing 
beta-carotene intake, either from diet alone or diet plus supplementation, was associated 
with higher risk neovascular AMD. This association also existed when the smoking status of 
the individuals was adjusted.  
In fact, one has to bear in mind about the possible harmful effect of beta-carotene 
supplementation. Apart from the skin coloration, changes in scotopic b-wave during 
electroretinography and crystal formation have also been shown with long-term beta-
carotene use 46. More importantly, daily supplementation of beta-carotene in smokers was 
associated with a higher mortality rate due to ischemic heart disease and lung cancer 29,30. 
Since smoking also increases the risk of AMD, beta-carotene supplementation should be 
avoided in smokers. Currently, no biological explanation has been offered to clarify the 
harmful effect of beta-carotene in human.  
Lutein and zeaxanthin are the only two carotenoids that exist in the human retina 34,35. They 
are particularly dense in the macula in humans, where they are referred to as macular 
pigment 34. Macular pigment is thought to be protective against retinal damage. Three case-
controlled studies showed that there was an inverse association between the macular 
pigment density in the human retina and the risk of AMD 47-49. In an early study 
investigating the effects of high dietary carotenoid intake, lutein and zeaxanthin were found 
to be the specific carotenoids that are most strongly associated with reduced risk of AMD 20. 
This result was also supported by two other studies. The population-based Pathologies 
Oculaires Liees a l'Age (POLA) Study measured the plasma carotenoid levels by high-
performance liquid chromatography (HPLC) in 899 subjects and correlated them with the 
risk of AMD 50. It was shown that high plasma levels of lutein and zeaxanthin were 
associated with a significant reduced risk of AMD. Similarly, a study in U.K. involving men 
and women aged 66 to 75 found that subjects with the lowest plasma level of zeaxanthin has 
a two-fold increased risk when compared with those with the highest plasma zeaxanthin, 
supporting the view that zeaxanthin may protect against AMD 51.  
Other studies also provide evidence in the association of lutein and zeaxanthin with AMD 
risk. In the Blue Mountains Eye Study, Flood et al reported a possible association between 
baseline intake of lutein and zeaxanthin and the 5-year incidence of early AMD 44. A longer, 
10-year follow-up study reported that high dietary lutein and zeaxanthin intake (top tertile) 
was associated reduced risk of incident neovascular AMD 45. Participants with above 
median intakes had a reduced risk of indistinct soft or reticular drusen.  
Conversely, several studies showed different results on the association of lutein and 
zeaxanthin. An early study in Beaver Dam (Beaver Dam Eye Study) reported no significant 
association between lutein and zeaxanthin and the risk of large drusen when 1,709 
participants were followed up for 5 years 23. In a prospective follow-up study of women in 
the Nurses' Health Study and men in the Health Professionals Follow-up Study, Cho et al 
followed 77,562 women and 40,866 men ≥50 years old for up to 18 years for women and up 
to 12 years for men. It was reported that lutein and zeaxanthin were not strongly related to 
either early or neovascular AMD risk 52. The Carotenoids in Age-related Eye Disease Study 
(CAREDS), an ancillary study of the Women's Health Initiative, followed 1,787 female 
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participants aged 50 to 79 for 4 to 7 years 53 and assessed their diet by a food frequency 
questionnaire. Subjects were divided according to their lutein and zeaxanthin intake, but 
there was no statistical difference between the amount of lutein and zeaxanthin intake and 
the prevalence of intermediate AMD. A later large prospective follow-up study also 
reported similar results 54. Two cohorts, the Nurses’ Health Study and the Health 
Professionals Follow-up Study which included 51,564 men and 71,494 women aged ≥50 
years were followed up for up to 18 years. Cho et al reported that there was no association 
between lutein/zeaxanthin intake and the risk of self-reported early AMD. Yet, a non-
significant and nonlinear inverse association between lutein/zeaxanthin intake and 
neovascular AMD risk was observed.  
More recently, lutein itself has gained special interests. Two prospective randomized 
controlled trials have investigated the association of lutein supplementation and the 
incidence of AMD. The larger Veterans LAST study (Lutein Antioxidant Supplementation 
Trial) involved 90 subjects with atrophic AMD who were randomly divided into three 
groups: lutein (10mg) group, lutein (10mg) plus additional antioxidants and nutrients 
group, and maltodextrin placebo group 55. Subjects were followed for 12 months and those 
who received lutein alone or lutein plus antioxidants and nutrients had improved visual 
acuity. Richer et al concluded that lutein alone or in combination with other nutritional 
supplements (including zinc, beta-carotene and vitamins C and E) is protective and slow 
down the progression of AMD. On the other hand, a smaller prospective trial measured the 
contrast sensitivity in 25 subjects after lutein supplementation (6mg) with vitamins and 
minerals or placebo over a 6-month period 56. No statistical difference was observed 
between the lutein and placebo group, suggesting no significant association between lutein 
supplementation and AMD. However, one has to be careful about these findings. The 
sample sizes in both studies were fairly small and the follow-up periods were limited to 12 
months or less.  
More supportive evidence came from a recent study in which participants in AREDS were 
genotyped for the hepatic lipase (LIPC) gene 57. Hepatic lipase is a protein in the high-
density lipoprotein cholesterol pathway and has been shown in a large genome-wide 
association study to be a novel locus for advanced AMD risk 58. It was observed in the 
AREDS participants that lower dietary lutein intake was significantly associated with 
increased risk of advance AMD, after controlling for the LIPC genotype. This suggests that 
high dietary lutein intake may reduce the risk of advanced AMD, after adjusting for genetic 
variants. 
Lutein is also a macular pigment. Due to lutein’s antioxidant properties and blue-light 
filtering capacity 36, it was hypothesized that macular pigment may provide protection 
against the development of AMD 59. The first prospective follow-up study, Muenster Aging 
and Retina Study (MARS), recently investigated the determinants of macular pigment 
optical density and its relation to AMD 60. Foveal macular pigment optical density was 
accessed in 369 participants including patients with different stages of AMD and healthy 
controls. In the 2.6-year follow-up study, it was observed that serum level of lutein, lutein 
supplementation in particular, was the strongest determinants of macular pigment optical 
density. However, the hypothetical protective effect of macular pigment in AMD could not 
be confirmed. On the other hand, a recent double-masked controlled study, Lutein 
Intervention Study Austria (LISA), investigated the association of 6-month lutein 
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supplementation with macular pigment optical density and visual acuity in 126 AMD 
patients randomly assigned to lutein supplementation or placebo 61. Weigert et al observed 
that lutein could significantly increase macular pigment optical density despite having no 
effect on mean differential light threshold or visual acuity. Interestingly, a significant 
correlation was found between the lutein-induced increase in macular pigment optical 
density and the change in mean differential light threshold and visual acuity. This finding 
suggests that patients who experience a pronounced increase in macular pigment optical 
density after lutein supplementation may benefit in terms of visual function.  
As lutein and zeaxanthin were not ready for manufacturing as a research formula, neither of 
them was included in the AREDS formula 28. The US Food and Drug Administration (FDA) 
has conducted an evidence-based review to evaluate the role of lutein and zeaxanthin in 
reducing the risk of AMD 62. After reviewing a number of intervention and observational 
studies, the FDA denied a health claim about the intake of lutein or zeaxanthin (or both) and 
the risk of AMD in 2006. However, in view of the conflicting findings, the National Eye 
Institute (Bethesda, Maryland, USA) launched the Age-Related Eye Disease Study 2 
(AREDS2) in 2006, hoping to resolve the link between carotenoids (lutein and zeaxanthin) 
intake and AMD protection 32,33. The AREDS2, a large, multi-centered, randomized trial, is 
currently underway to address the effects of high dose lutein and zeaxanthin 
supplementation and/or omega-3 fatty acids on the progression of AMD. Beta-carotene, 
which increases the risk of lung cancer in smokers 29,30, is removed from the AREDS2 
formula. Another on-going, similar randomized controlled trial is the Carotenoids in Age-
Related Maculopathy (CARMA) Study 63. In this study, 433 participants with either early 
AMD features or any level of AMD in one eye and advanced AMD in the fellow eye were 
recruited. Either lutein and zeaxanthin, in combination with antioxidants (including vitamin 
C, vitamin E, zinc, and copper) or placebo was given. Again, beta-carotene was excluded in 
the preparation due to the increased risk of lung cancer in smokers 29,30.  
Although the beneficial effects have not been proven, lutein and zeaxanthin are included in 
daily supplements and food additives and can be obtained over the counter. Moreover, the 
addition of crystalline lutein into food and beverage products is considered GRAS 
(generally recognized as safe) and is approved by the FDA 64. Lutein toxicity studies in 
animals using high doses of purified crystalline lutein revealed no unfavorable events 64 and 
no adverse events are reported for lutein and zeaxanthin at doses up to 40 mg/day in 
human for 2 months 65. The risk profile of lutein was also recently reviewed in 2006 by the 
Council for Responsible Nutrition (CRN) in Washington, D.C. It was concluded that apart 
from the reversible skin discoloration, no other adverse effects were observed 66. The CRN 
suggested an upper level of intake for lutein up to 20 mg/day. Currently, the average daily 
intake for lutein and zeaxanthin is 2.0-2.3 mg/day for men and 1.7-2.0 mg/day for women 
in United States (Food and Nutrition Board, 2001).  
In view of their potential benefits as well as minimal side effects, lutein and zeaxanthin may 
be recommended for those who are keen and at risk of AMD 27.  
3.3 Vitamin C (L-ascorbic acid) 
Vitamin C is a water-soluble nutrient that is synthesized in almost all animals and plants. It 
is well known for its potent antioxidant activities 67,68. It also acts as an important co-factor 
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in mammals as in the synthesis of collagen; therefore vitamin C is used in the treatment and 
prevention of scurvy. In ophthalmology, there has not been any randomized controlled trial 
in assessing the efficacy of vitamin C as a single supplement in AMD. Yet, in other studies 
combining vitamin C with other supplements, data on the protective effects of vitamin C has 
been mixed. Vitamin C is shown to be beneficial in the AREDS study 19. In two large 
prospective studies of 135 men and 329 women with up to 18 years of follow-up 52, it was 
found that higher fruit intake was related to a reduced risk of neovascular age-related 
maculopathy but none of the vitamins (including vitamin C) or carotenoids examined was 
clearly related to the disease. In a population-based cohort study involving 1,586 middle-
aged and older adults, the researchers found no significant associations between the risk of 
large drusen and intake of vitamin C 23. Another population-based cohort study even 
suggested that an increasing baseline vitamin C intake from diet and supplements was 
associated with an increased risk of incident early age-related maculopathy when compared 
with the lowest quintile 44 
3.4 Vitamin E (α-tocopherol) 
Vitamin E is a collective term for a group of natural lipid-soluble compounds containing the 
tocopherols (α-, β-, γ- and δ-) and tocotrienols (α-, β-, γ- and δ-) with antioxidant properties. 
Among them, α-tocopherol is the only form to meet human requirements. In the eye, α-
tocopherol can be found in the retina, RPE and choroid 69. Its concentration in the retina 
increases after oral supplements 70. 
As an antioxidant and a nutritional factor, vitamin E has been explored in its association 
with prevention of AMD. Again, data for vitamin E have been mixed. Some studies reported 
that higher intake are associated with lower risks of AMD or signs 23,42,71 whereas some 
concluded no associations 45,52,72,73.  
In particular, three large randomized controlled trials have assessed vitamin E in the 
incidence of AMD. The Alpha-Tocopherol and Beta-Carotene (ATBC) Study involved over 
29,000 smoking males aged 50 to 69 years who were randomly assigned to alpha-
tocopherol (50 mg/day), beta-carotene (20 mg/day), both of these, or placebo 43. Of these, 
an end-of-trial ophthalmological examination was performed in a random sample of 941 
participants aged 65 years or more. No beneficial effect of long-term supplementation 
with alpha-tocopherol on the occurrence of AMD was detected among smoking males. In 
the Vitamin E Cataract and Age-related Maculopathy Trial (VECAT), 1,193 healthy 
volunteers aged between 55 and 80 years were randomly given either vitamin E (500IU = 
335 mg) or placebo daily for 4 years 74. In the study, the incidence of early AMD in those 
receiving vitamin E (8.6%) was similar to those on placebo (8.1%) whereas for late disease 
the incidence was 0.8% versus 0.6%. Again, daily vitamin E supplement does not prevent 
the development or progression of early or later stages of AMD. In the Women’s Health 
Study (WHS) 75, a large scale randomized trial of women, 39,876 healthy female health 
professionals were randomly assigned to receive with natural source vitamin E (600IU) or 
placebo on alternate days. There were 117 AMD cases in the vitamin E group versus 128 
cases in the placebo group after 10 years of treatment and follow-up. Similar to other 
studies, no large beneficial or harmful effect on risk of AMD was observed in long term 
vitamin E supplementation.  
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More importantly, a negative association between vitamin E and AMD was recently 
reported. In the Blue Mountains Eye Study involving an Australian population–based 
cohort, Tan et al reported that high vitamin E intake was associated with increased risk of 
late AMD, suggesting a harmful effect of dietary vitamin E on risk of AMD 45. However, one 
has to be cautious about these results. There was a moderate loss of participants in this 
particular study, while the levels of vitamin E intake between participants followed up and 
not followed up were significantly different. The authors mentioned that this might affect 
the interpretation of the observed results.  
3.5 Zinc 
Zinc is an essential trace element for almost all organisms including plants, animals and 
microorganisms. It has a multitude of biological roles, playing a fundamental role in cellular 
metabolism. For example, it plays a structural role in a large number of transcription factors 
containing zinc fingers and similar structural motifs. Most importantly, it was first shown to 
be required for the catalytic activity of carbonic anhydrase 76. Later studies showed that zinc 
has a catalytic or structural role in at least 300 zinc metalloenzymes 77-79, influencing many 
metabolic reactions. In fact, approximately 10% of the human genome encodes for proteins 
that can bind zinc 80. 
In the human body, there are about 2-3 g of zinc, making it the second most abundant trace 
element 79,81. In ocular tissues, the concentration of zinc is unusually high when compared 
with other tissues 82. In the eye zinc is most abundant in the retina and choroid, followed by 
ciliary body, iris, optic nerve, sclera, cornea, and lens 83. A number of functions of zinc in the 
retina have been suggested, including modulation of retinal synaptic transmission, 
modification of photoreceptor plasma membrane, involvement in retinal vitamin A 
metabolism, regulation of light-rhodopsin reaction within the photoreceptor, and 
antioxidant activity 84,85.  
There are subtle ocular manifestations associated with zinc deficiency. In a prospective, 
randomized, double-masked, placebo-controlled investigation of the effects of oral zinc 
administration on the visual acuity outcome in 151 subjects with drusen or macular 
degeneration, the treatment group had significantly less visual loss than the placebo group 
24. As elderly patients are found to be at higher risk of zinc deficiency 86, this may suggest an 
increased risk of vision loss from AMD in elderly patients.  
For the past three decades, there have been considerable interest and controversy related to 
zinc supplementation in AMD patients. To date, results on zinc supplementation and AMD 
have been mixed. As described above, Newsome et al reported significant reduction in 
visual loss in AMD patients when supplemented with oral zinc 24. Moreover, Mares-
Perlman et al reported a weak protective effect of dietary zinc on the development of some 
forms of early AMD 71. In the large double-masked clinical trial, The Age-Related Eye 
Disease Study (AREDS), involving 11 centers, participants taking zinc alone demonstrated 
an odds reduction of 0.75 for the development of advanced AMD. Zinc significantly reduced 
the odds of developing advanced AMD in the higher-risk group. A population-based cohort 
study reported that high dietary zinc intake was associated with a lower risk of incident 
AMD 42. In the Beaver Dam Eye Study, it was observed that there is a significant inverse 
association between zinc and the incidence of pigmentary abnormalities, but there was no 
www.intechopen.com
 
Age Related Macular Degeneration – The Recent Advances in Basic Research and Clinical Care 
 
198 
relationship between zinc intake and incidence of early AMD 23. In fact, an early study by 
the Eye Diseases Case-Control Study Group reported no association between serum zinc 
levels and risk of neovascular AMD 40. In a 2-year, double-masked, randomized, placebo-
controlled study, Stur et al reported that oral zinc substitution has no short-term effect in 
patients who have an exudative form of AMD in one eye 87. Unfortunately, this study was 
prematurely terminated because of no beneficial effects found in first 40 patients at 24 
months. In addition, two large prospective studies involving 66,572 women and 37,636 men 
do not support a lowered AMD risk associated with higher zinc intake 88. The Blue 
Mountains Eye Study Group reported no significant association between baseline zinc 
intake from diet or supplements and the 5-year incidence of early Age-related 
maculopathy44.  
A systematic review and meta-analysis involving four prospective cohort studies 
23,42,44,88reported that a pooled odds ratio of zinc for early AMD was 0.91 (95% CI 0.74 to 
1.11). Another meta-analysis reported that zinc supplementation can slow down AMD 
progression (adjusted odds ratio = 0.77, 95% CI 0.62 to 0.96) 89. 
Although the evidence is conflicting, recent studies support a protective role of zinc in AMD 
progression. The AREDS study indicated that the beneficial effect of zinc supplementation 
was of a similar order to that of vitamin supplementation. Despite the 5-year findings by 
The Blue Mountains Eye Study Group 44, later studies by the same group published the 10-
year data in which individuals with total zinc intake in the highest decile are less likely to 
develop early or any AMD 45.  
Zinc intake and the genetic risk of AMD has also been assessed. In the AREDS population, 
the single nucleotide polymorphism in the CFH (Y402H, rs1061170) and LOC387715/ARMS2 
(A69S, rs10490924) genes of 876 participants who were considered at high risk was 
genotyped 90. The findings suggest that there is an interaction between CFH genotype and 
treatment with antioxidant plus zinc when compared with placebo. Moreover, a recent 
study involving 2,167 individuals from the population-based Rotterdam Study at genetic 
risk of AMD assessed their dietary intake at baseline using a semi-quantitative food 
frequency questionnaire and determined the genetic variants using TaqMan assay 91. In this 
nested case-control study, it was observed that there is a significant possibility of biological 
interaction between CFH Y402H and zinc as well as between LOC387715 A69S and zinc (p < 
0.05). Moreover, individuals with homozygous CFH Y402H with dietary intake of zinc in 
the highest tertile reduced their hazard ratio of early AMD from 2.25 to 1.27.  
Again, one has to be cautious about the risks of high dose supplementary intake of zinc. In 
the AREDS study, more people in the zinc group reported difficulty in swallowing the 
tablets (17.8% vs. 15.3%, p < 0.04) 19. Circulatory adverse experiences were also more 
frequently reported in individuals receiving zinc. Hospitalizations due to genitourinary 
problems as well as mild or moderate symptoms are also more frequent in these 
participants. In fact, it was found that there is a significant increase in hospital admissions 
for urinary complications in patients with high zinc supplementation (11.1% vs 7.6%, p = 
0.0003) 92. The risk was greatest in male patients (RR 1.26, 95% CI 1.07-1.50, p = 0.008). 
Significant increase in urinary tract infections was also found (p = 0.004), especially in 
females. Another problem was gastrointestinal symptoms. Of 286 participants, 5/146 zinc-
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treated participants withdrew from the studies due to gastrointestinal symptoms when 
compared with 2/140 in the placebo group 24,87. 
3.6 Omega-3 Long chain polyunsaturated fatty acids 
The retina contains abundant fatty acids, about 30% of which are polyunsaturated fatty 
acids 93. Polyunsaturated fatty acids are classified into 2 groups: ω-3 and ω-6 depending on 
the position of the first double bond from the methyl end of the molecule. Docosahexaenoic 
acid (DHA), an omega-3 fatty acid, is highly enriched in the retina, particularly in the disc 
membrane of photoreceptor outer segments 94. DHA is the major polyunsaturated fatty acid 
in cerebral gray matter as well. Yet, the specific role of DHA in the eye is not clear. DHA has 
been shown to be important for photoreceptor survival 95-98. DHA may have a role in 
modulating G protein-coupled signaling pathways that are involved in visual transduction 
99. DHA may also affect rhodopsin function during photoreception by influencing the 
membrane’s biophysical properties 100,101. In rhesus monkeys, dietary depletion of alpha-
linolenic acid, a dietary precursor of DHA, resulted in undetectable plasma DHA level and 
more importantly, abnormal retinogram and visual impairment 102,103. Nonetheless, DHA 
supplementation is effective in improving retinal function in a patient with autosomal 
dominant Stargardt-like retinal dystrophy 104. The importance of DHA in retinal function 
may suggest a possible beneficial role of DHA in retinal disease such as AMD. 
Another omega-3 fatty acid, eicosapentaenoic acid (EPA), is the precursor of eicosanoids in 
the body. It can act as a competitive inhibitor of arachidonic acid conversion to pro-
inflammatory eicosanoids prostaglandin E(2) and leukotriene B(4) 105. As inflammation 
plays a role in the pathogenesis of AMD, EPA may be one of the protective factors in AMD. 
Supplementation of omega-3 fatty acids, DHA and EPA in particular, has received much 
interest in association with lowering the risk of AMD. Although DHA can be synthesized 
from alpha-linolenic acid in the body, the process is ineffective. DHA and EPA can readily 
be obtained from marine fish oils in the diet. Based on their roles in retinal function and 
inflammation, dietary modification and supplementation of omega-3 fatty acids have 
become attractive alternatives in lowering the risk of AMD. 
Many studies have provided evidence for a protective role of omega-3 fatty acids 
supplementation in AMD risk 91,106-117. The first study evaluating the relationship between 
dietary fat and AMD was published by Mares-Perlman et al 106. They reported that high 
intake of saturated fat and cholesterol was associated with increased risk for early AMD. 
Later, a prospective follow-up study of participants in the Nurses' Health Study and the 
Health Professionals Follow-up Study showed that total fat intake was positively associated 
with increased risk of AMD 108. Yet, a cross-sectional study involving participants in the 
Third National Health and Nutrition Examination Survey found no association between 
dietary fat and AMD risk. However, this study assessed only one eye per patient, thereby 
may have decreased the observed AMD prevalence. 
There are further investigations into the association of omega-3 fatty acids with AMD risk. 
As dietary omega-3 fatty acids are obtained from marine fish oils, fish intake was also 
investigated. Earlier study on fish intake was performed in the Blue Mountain Eye Study 
population. In this cross-sectional, population based study, Smith et al showed that a higher 
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fish consumption was associated with decreased odds of late AMD 107. After 5 years of 
follow-up Chua et al reported that fish consumption at least once a week was protective 
against early AMD, whereas fish consumption at least 3 times per week could reduce the 
incidence of late AMD 110. After 10 years of follow up in the same cohort, Tan et al suggested 
that a regular weekly serving of fish was associated with a reduced risk of early AMD 116. 
Interestingly, it was also noted that fish consumption of more than one serving per week did 
not have a significant protective effect in reducing AMD risk in this cohort, suggesting a 
threshold effect. These findings are supported by other studies as well. Seddon et al in a 
multicenter eye disease case-control study reported that higher intake of omega-3 fatty acids 
and fish was associated with a lower risk for AMD among individuals with low linoleic acid 
intake 109. More evidence on the protective role of omega-3 fatty acid came from a recent US 
Twin Study of Age-Related Macular Degeneration. This study investigated the association 
between dietary fat intake and fish consumption and risks of AMD in 681 twins 111 and 
found that both omega-3 and fish intake reduced the risk of AMD.  
Oily fish rich in omega-3 fatty acids are also found to be beneficial in two European studies. 
The population-based POLANUT study from Southern France found that fatty fish intake 
was protective against AMD when comparing more than once a month and less than once a 
month and after multvariate adjustment 112. Interestingly, total and white fish intake has no 
significant association with AMD risk. Another population-based study, EUREYE, showed 
that oily fish intake (at least once per week versus less than once per week) was associated 
with significant reduction of risk for neovascular AMD 114. Similar findings were also 
observed for either DHA or EPA intake. 
Among the AREDS participants, a prospective cohort of individuals with neovascular AMD 
and central geographic atrophy was also analyzed for the relationship of omega-3 fatty acids 
and AMD. It was observed that dietary total omega-3 fatty acids or DHA intake was 
inversely associated with neovascular AMD 113. Similar findings were also observed with 
fish consumption. Further studies showed that dietary omega-3 fatty acids intake is 
associated with a decreased risk of progression from bilateral drusen to central geographic 
atrophy 115.  
In addition, the association between omega-3 fatty acids and genetic risk of AMD is 
investigated. In the Blue Mountains Study group, 1881 participants were genotyped for 
complement factor H (CFH) genetic variants 117. Wang et al reported that AMD risk 
increased with each additional C allele. Also, weekly compared with less than weekly 
consumption of fish was associated with reduced late AMD risk in participants with the CC 
genotype but not the CT or TT genotypes. This study provided evidence that weekly 
consumption of fish is protective on the development of late AMD, but not early AMD, 
among individuals with genetic susceptibility to AMD due to the Y402H variant. On the 
other hand, the dietary intake of 2167 individuals was assessed at baseline in a recent 
population-based Rotterdam study 91. Ho et al reported a possible interaction between 
EPA/DHA and either CFH Y402H or LOC387715 A69S. The authors also suggested that 
high dietary intake of omega-3 fatty acids may reduce the risk of early AMD in those who 
are at high genetic risk. 
Taken together, much data suggests that dietary omega-3 fatty acids intake and fish 
consumption are protective against AMD. Results from a recent meta-analysis also 
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supported the protective role of omega-3 fatty acids supplementation 118. It was reported 
that dietary intake of omega-3 fatty acids was associated with reduced risk of late AMD 
while fish consumption (at least twice a week) was associated with reduced risk of both 
early and late AMD. However, the authors also cautioned that due to insufficient evidence, 
few prospective studies and no randomized clinical trials, recommendation for a routine 
omega-3 fatty acids supplementation and fish consumption for AMD prevention is not 
supported. A similar conclusion was also reached in another systematic review 119. 
Hopefully, more definite answers on the protective role of omega-3 fatty acids will be 
provided by the ongoing AREDS2 randomized, multi-center trial.  
3.7 B vitamins 
B vitamins are a group of water-soluble compounds that are important in cell metabolism. 
The members of interest in AMD studies are folic acid, vitamin B6 (pyridoxine) and vitamin 
B12 (cyanocobalamin) because of their ability to reduce homocysteine levels in intervention 
studies 120. Homocysteine is an amino acid formed during the metabolism of methionine. It 
can either be recycled back into methionine or converted into cysteine with the help of B-
vitamins. 
Serum level of homocysteine has been implicated in increasing the risk of AMD. Recent 
cross-sectional 121-123and case-control studies 124-128 showed that there may be a direct 
association between homocysteine level in the blood and AMD. Hyperhomocysteinemia 
(plasma homocysteine > 15µmol/L) can also induce vascular endothelial dysfunction 129-131. 
It was therefore proposed that lowering blood homocysteine levels with folic acid, vitamin 
B6 and vitamin B12 supplementation may help to reduce the risk of AMD.  
In the Women’s Antioxidant and Folic Acid Cardiovascular Study (WAFACS), 5,442 female 
health professionals participated in this randomized, double-masked, placebo controlled 
trial 132. Christen et al reported that daily supplementation with folic acid/B6/B12 reduce the 
risk of AMD in this large cohort of females after an average of 7.3 years of treatment and 
follow-up. Yet, disease report in this study was done by self-report questionnaires or 
medical records while no ophthalmic examinations were performed. More evidence and 
further research in other groups are needed despite the interesting association between folic 
acid/B6/B12 supplementation and AMD prevention.  
3.8 Berry extracts 
Diets rich in fruits, nuts, and vegetables have long been considered to be an excellent source 
of antioxidants. There has been growing interest on berry extracts due to their high 
antioxidant properties. Among the berries, blueberries have been of specific interest because 
of their high antioxidant capacity (in some cases as high as 40−50 μmol Trolox 
equivalents/g) 133. Indeed, of all the fresh fruits and vegetables tested to date, data indicate 
that blueberries have the highest antioxidant capacity, as estimated using the average 
oxygen radical absorbance capacity (ORAC) values 133-135. Polyphenols in blueberries, 
specifically the anthocyanins that give the fruit its blue color, are the major contributors to 
antioxidant activity 133.  
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Anthocyanin is a water-soluble pigment present in all plants and is richly concentrated in 
berries. It is a powerful antioxidant in vitro 136. It can absorb blue-green light and protects the 
cells from light stress in plant studies 137. In laboratory studies, anthocyanin may protect the 
eyes from degenerative diseases such as AMD 138-140. Yet, the evidence for the potential 
health effects of anthocyanin is mostly laboratory-based 141.  
Another berry that recently received lots of interest is the fruit of Lycium barbaurm, also 
called wolfberry or Gouqizi, a commonly used herb in Chinese Traditional Medicine. It is 
also taken as food in Asian countries. It is well known for improving eye sight. Increasing 
lines of evidence showed that the polysaccharides in Lycium barbaurm can exhibit anti-aging 
142 and anti-oxidative effects 143. Other properties such as anti-tumor effects, cytoprotection, 
neuromodulation, and immune modulations have also been suggested 142,144. Unfortunately, 
most evidence for its beneficial effects is limited to the laboratory level.  
At this moment, there are no legal requirements for quality control in the preparation of 
these extracts. It is not obligatory to disclose the content and the production method. 
Moreover, the dosage and frequency are unclear while potential toxicity and long-term side 
effects remain to be investigated. A lot of investigation is needed before the potential of 
berry extracts in prevention of AMD can be hinted. Currently, berry extracts should not be 
recommended 27. 
4. Future directions 
Observational studies have shown beneficial effects from dietary supplementation of lutein 
and zeaxanthin as well as omega-3 fatty acids in the development of AMD. They are 
currently tested in AREDS2, the multi-centered randomized clinical trial launched by the 
National Eye Institute in 2006. The association of oral formulations containing lutein and 
zeaxanthin, and/or DHA and EPA, with the progression of AMD is being assessed. In 
AREDS2 participants will be followed for 5 years. Hopefully, data will be available by the 
end of 2012. Similarly, the ongoing CARMA study will also provide invaluable data on the 
protective effects of lutein and zeaxanthin in combination with antioxidants (vitamin C, 
vitamin E and zinc) with the exclusion of DHA and EPA.  
5. Conclusions 
To date a large body of evidence has supported a protective role of nutritional supplements 
in the development and progression of AMD. In particular, strongest evidence is present for 
the protective effect of lutein, zeaxanthin, DHA, and EPA. On the other hand, beta-carotene 
and vitamin E may have detrimental effects. While awaiting a further proof of the effects of 
lutein, zeaxanthin, DHA, and EPA, the AREDS formulation remains the best 
recommendation so far, although not without risk and maybe only for high-risk individuals. 
One concern for the AREDS formulation is the higher risk of lung cancer in smokers with 
daily beta-carotene supplementation. Therefore, in offering nutritional supplements to 
patients, physicians should consider on a case-by-case basis and fully explain the potential 
side effects from a long-term regular intake. It is also important to remind the patients that 
even with the AREDS formulation, AMD can still occur. It is equally important to teach the 
patients self-monitoring methods such as usage of the Amsler grid. Regular fundal 
examinations by ophthalmologists should also be strongly encouraged. 
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